CClinicalTrials.gg
RecruitingNCT05128149PKU_GuideUpdated Apr 13, 2025

Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?

An observational study in Phenylketonurias, sponsored by University Children's Hospital, Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by University Children's Hospital, Zurich · Observational

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
200
Ages
10 Years and older
Sex
All
01

Study summary

Treatment of PKU implies for most patients that with strict adherence to dietary treatment they can achieve excellent neurocognitive outcome. Dietary treatment, though, is hard to comply to every day and with every single meal. Unsurprisingly, health-related quality of life (HrQol) is negatively affected if patients have to follow a dietary regime of this kind. Adherence to treatment in PKU is very variable. Factors of significant impact on adherence to treatment and well-being in chronic disease such as self-efficacy or parenting stress have not yet been widely investigated in PKU patients.

The ideal treatment prescription (and guideline) recommends as much as necessary and as little as possible, based on the best evidence available. Patients should neither be deprived of treatment options nor be exposed to overtreatment.

This study investigates adherence, metabolic control, HrQol in PKU patients treated by centres which follow different guidelines

02

Conditions studied

  • Phenylketonurias

Browse trials for

03

In context

Phenylketonurias

183 studies on the registry are indexed under Phenylketonurias; 38 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 60 observational studies indexed under Phenylketonurias.

Browse Phenylketonurias studies →

Lead sponsor

University Children's Hospital, Zurich is the lead sponsor of 92 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

PKU patients > 10 years and their parents

Eligibility criteria

Inclusion Criteria:- Patients with PKU from age 10 years requiring dietary and / or pharmacological treatment according to locally applied guidelines

  • Parents of patients with PKU aged 10 to 18 years requiring dietary and / or pharmacological treatment according to locally applied guidelines
  • Ability and willingness to answer the questionnaires and follow the study procedures
  • Informed consent as documented by signature

Exclusion criteria for patients and parents :

  • Inability to follow the procedures of the study, e.g. due to language problems or severely reduced health status
  • Pregnant patients or patients who have disclosed to their physician that they are planning a pregnancy in the near future
  • Hyperphenylalaninaemia or mild forms of PKU or other inborn errors associated with elevated Phe but not requiring dietary and / or pharmacological treatment according to locally applied guidelines
  • No inform
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Phe values

    biochemical marker for PKU

    Time frame: report on measurements from past 24 months

Secondary outcomes

  1. Health-related quality of life

    PKU-QoL© Questionnaire

    Time frame: one hour

  2. Self-efficacy

    10 items Self-efficacy scale (Schwarzer\& Jerusalem)

    Time frame: one hour

  3. Burden on family (patients from 10-18 years)

    Revised Impact on Family Scale

    Time frame: one hour

07

Study locations

1 of 1 sites recruiting
  • University Childrens Hospital Zürich
    Zürich, 8032, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05128149
Lead sponsor
University Children's Hospital, Zurich
Collaborators
UChildrenVienna, University Children's Hospital Basel, Insel Gruppe AG, University Hospital Bern
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 15, 2021
Primary completion
Mar 30, 2025
Completion
Dec 31, 2025 (estimated)
Last update
Apr 13, 2025

Study contacts

Martina Huemer, Prof
Contact
martina.huemer@kispi.uzh.ch
+41 44 2660

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion